Lucira Health, Inc. (LHDX)

Lucira Health (NASDAQ: LHDX ) stock is falling on Friday after the company's shares have seen extreme volatility throughout the week. That includes a massive rally earlier this week that saw the company's shares gain as much as 871% since its closing price on Friday.

Lucira Health Inc. (NASDAQ: LHDX) shares spiked up 264% to close at $0.52 on a massive 278 million shares traded on the announcement of FDA approval for its combination at-home COVID-19 and a flu test. The over-the-counter (OTC) 30-minute at-home rapid test can detect influenza A and B and the SARS-CoV-2 virus using nasal swabs.

Using liquidity and volume to make money with penny stocks The post Penny Stocks: The Importance of Liquidity and Volume appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Cheap penny stocks to watch before next week. The post Penny Stocks To Buy Now?

Lucira Health Inc shares have added more than 300% after it announced on Friday that the US Food and Drug Administration (FDA) has granted emergency use authorization for its combination COVID-19 and flu test for use at home and in non-laboratory settings, just days after the company filed for Chapter 11 bankruptcy. The company said the molecular test delivers results in 30 minutes or less from a shallow nasal swab and demonstrated similar performance for COVID-19 and Influenza A and B compared to highly sensitive lab-based PCR tests in clinical trials.

Lucira Health (NASDAQ: LHDX ) stock is rocketing higher on Monday thanks to an update from the FDA. The big news here is Lucira Health getting FDA approval for its at-home Covid-19 and flu combination tests.

Lucira Health Inc. LHDX, +13.45% shares more than doubled in the extended session Friday after the Food and Drug Administration authorized use of its at-home test that can detect both the flu and the virus that causes COVID-19. Shares of Lucira soared more than 150% after hours, following a regular session gain of 13.5% to close at 14 cents.

Lucira Health (NASDAQ: LHDX ) stock is taking a beating on Thursday after the company filed for Chapter 11 bankruptcy protection. To go along with that filing, Lucira Health says it intends to sell its business during the bankruptcy process.

AppHarvest (APPH), Lucira Health (LHDX), Lucid Group (LCID), Life Time Group (LTH) & Ameriprise Financial (AMP) not only have made the most of the January rally but also are poised to gain further this year.

Avoid making these penny stocks trading mistakes this year The post Biggest Penny Stocks Trading Mistakes to Avoid in 2023 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

One of the biggest upside movers in today's upside-down market is medical technology company Lucira Health (NASDAQ: LHDX ). This little-known maker of PCR tests for various infectious diseases is on a tear, with LHDX stock up more than 400% as of early afternoon trading.

Lucira Health, Inc. (NASDAQ:LHDX ) Q3 2022 Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Greg Chodaczek – Gilmartin Group Erik Engelson – President and Chief Executive Officer Dan George – Chief Financial Officer Conference Call Participants Operator Good afternoon, ladies and gentlemen, and welcome to the Lucira Health Third Quarter 2022 Earnings Conference Call. At this time all participants are in a listen-only mode.

EMERYVILLE, Calif., Aug. 23, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (“Lucira Health” or “Lucira”), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced that the company will participate in the Gilmartin Group Emerging Growth Company Showcase on August 31st, 2022.

Lucira Health, Inc. (NASDAQ:LHDX ) Q2 2022 Earnings Conference Call August 15, 2022 4:30 PM ET Company Participants Louisa Smith – Investor Relations Erik Engelson – President and Chief Executive Officer Dan George – Chief Financial Officer and Treasurer Conference Call Participants Griffin Soriano – William Blair John Kim – Bank of America Rahul Rakhit – LifeSci Capital Operator Good afternoon, ladies and gentlemen, and welcome to Lucira Health Second Quarter Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.

EMERYVILLE, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (“Lucira Health” or “Lucira”), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced that the company will report second quarter 2022 financial results on, Monday, August 15, 2022. Lucira's management will host a conference call and webcast at 1:30 p.m. PT / 4:30 p.m. ET that day to discuss the financial results and provide a corporate update.

Lucira Health, Inc. (NASDAQ:LHDX ) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Louisa Smith - Gilmartin Group, IR Erik Engelson - President, CEO Dan George - CFO Conference Call Participants Brian Weinstein - William Blair Rahul Rakhit - LifeSci Capital Operator Good afternoon, ladies and gentlemen. And welcome to the Lucira Health First Quarter Earnings Conference Call.